Vestnik On-line
Orenburg State University november 29, 2021   RU/EN
Headings of Vestnik
Pedagogics
Psychology
Other

Search
Vak
Антиплагиат
Orcid
Viniti
ЭБС Лань
Rsl
Лицензия Creative Commons

2013, № 4 (153)



Kachalina G.F., Pedanova Ye.K., Solomin V.A., Klepinina O.B. MORPHOLOGICAL AND FUNCTIONAL RESULTS OF CENTRAL SEROUS CHORIORETINOPATHY TREATMENT IN SUBTHRESHOLD MICROPULSE LASER THERAPY WITH 577 NM WAVELENGTH (PRELIMINARY REPORT)The root of the onset and progression of central serous chorioretinopathy (CSR) is a series of disorders at the level of retinal pigment epithelium cells and choroid (hyperpermeability of vessels). The subthreshold micropulse 577 nm wavelength laser therapy is an effective and safe method of CSR therapy affecting all parts of the pathological process.Key words: central serous chorioretinopathy, subthreshold micropulse laser therapy, retinal pigment epithelium, hyperpermeability of choroidal vessels.

Download
References:

1. M. Moschos, D. Brouzas, C. Koutsandrea et al. Assessment of central serous chorioretinopathy by optical coherence tomography and multifocal electroretinography // Ophthalmologica. — 2007. — Vol.221 (5). — P. 292-298.

2. Balashevich L.I., Kasimov E.M., Iskanderova N.G. et al. Current views on the etiology and pathogenesis of central serous chorioretinopathy // Ophthalmosurgery. — 2007, — №2. — P.63-67.

3. Kitaya N., Nagaoka T., Hikichi T., et al. Features of abnormal choroidal circulation in central serous chorioretinopathy // Br J Ophthalmol. — 2003, — Vol.87. — P.709–712.

4. Imamura Y., Fujiwara T., Margolis R., et al. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy // Retina. — 2009, — Vol.29. — P.1469–1473.

5. Sekiryu T., Iida T., Maruko I. et al. Infrared Fundus Autofluorescence and Central Serous Chorioretinopathy // Investigative Ophthalmology & Visual Science. — 2010, — Vol.51, No. 10. — P.4956-4962.

6. Iida T., Kishi S., Hagimura N., et al. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy // Retina. — 1999, — Vol.19. — P.508–512.

7. Ross A., Ross A.H., Quresh Mohamed. Review and update of central serous chorioretinopathy // Curr Opin Ophthalmol. — 2011. — Vol.22 — P.166-173.

8. Luttrull1 J. K., Dorin G. Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review // Current Diabetes Reviews, 2012, 8. –P. 274-284.

9. Dorin G. Subthreshold and micropulse diode laser photocoagulation // Seminars in Ophthalmology. — 2003, — Vol.18. — P. 147-153.

10. Yanling Liu, Lan Franco Leo,Corban McGregor et al. Pigment Epithelium-Derived Factor (PEDF) Peptide Eye Drops Reduce Inflammation, Cell Death and Vascular Leakage in Diabetic Retinopathy in Ins2Akita Mice // Mol Med. 2012; 18(1): 1387–1401.

11. Gupta B., Elagouz M., McHugh D. et al. Micropulse diode laser photocoagulation for central serous chorio-retinopathy // Clin Experiment Ophthalmol. 2009 Nov;37(8):801-5.

12. Lanzetta P, Furlan F, Morgante L, Veritti D. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study // Eur J Ophthalmol. 2008 Nov-Dec;18(6):934-40.

13. Maia A. Micropulse Treatment for Central Serous Retinopathy // RETINA TODAY. — 2010, P. 17-18.

14. Cardillo A. 577 nm MicroPulse Laser Therapy:Addressing the Immediate Need of Our Patients With DME // RETINA TODAY. — 2012, P. 11-14.

15. Koss MJ, Beger I, Koch FH. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy // Eye (Lond). 2012 Feb;26(2):307-14

16. Ogata N, Tombran-Tink J, Jo N. et al. Upregulation of pigment epithelium-derived factor after laser photocoagulation // Am J Ophthalmol. 2001 Sep;132(3):427-9.

17. Hattenbach LO, Beck KF, Pfeilschifter J. et al. Pigment-epithelium-derived factor is upregulated in photocoagulated human retinal pigment epithelial cells// Ophthalmic Res. 2005 Nov-Dec;37(6):341-6.

18. Tombran-Tink J. PEDF in angiogenic eye diseases // Curr Mol Med. 2010 Apr;10(3):267-78.

19. Ueda S, Yamagishi SI, Okuda S. Anti-vasopermeability effects of PEDF in retinal-renal disorders // Curr Mol Med. 2010 Apr;10(3):279-83.


About this article

Authors: Pedanova E.K., Kachalina G.F., Solomin V.A., Klepinina O.B.

Year: 2013


Editor-in-chief
Sergey Aleksandrovich
MIROSHNIKOV

Crossref
Cyberleninka
Doi
Europeanlibrary
Googleacademy
scienceindex
worldcat
© Электронное периодическое издание: ВЕСТНИК ОГУ on-line (VESTNIK OSU on-line), ISSN on-line 1814-6465
Зарегистрировано в Федеральной службе по надзору в сфере связи, информационных технологий и массовых коммуникаций
Свидетельство о регистрации СМИ: Эл № ФС77-37678 от 29 сентября 2009 г.
Учредитель: Оренбургский государственный университет (ОГУ)
Главный редактор: С.А. Мирошников
Адрес редакции: 460018, г. Оренбург, проспект Победы, д. 13, к. 2335
Тел./факс: (3532)37-27-78 E-mail: vestnik@mail.osu.ru
1999–2021 © CIT OSU